Cancer Research & Treatment Fund
This organization has already been registered
Someone in your organization has already registered and setup an account. would you like to join their team?Profile owner : c***y@c*t.o*g
Mission Statement
Since 1968, CR&T has funded the world's most promising physician-scientists, equipping them with the resources to advance the treatment of various types of blood cancers, including myeloproliferative neoplasms (MPNs), leukemia, non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma, as well as other common cancers, such as breast cancer. To learn more, visit www.crt.org.
About This Cause
Since 1968, CR&T has funded the world's most promising physician-scientists, equipping them with the resources to advance the treatment of various types of blood cancers, including myeloproliferative neoplasms (MPNs), leukemia, non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma, as well as other common cancers, such as breast cancer. The cornerstone of CR&T's research strategy is our commitment to the Richard T. Silver, MD Myeloproliferative Neoplasm (MPN) Center at Weill Cornell Medical College in New York City. CR&T is providing a multi-year, $4.7 million grant to this translational research and treatment center, which was officially dedicated in February 2014. Our support is key to building a world-class center that focuses on these rare blood cancers, which can cause serious -- and sometimes life-threatening -- complications. This is the most recent of many crucial research initiatives. Over the years, CR&T investigators have: • Conducted initial clinical studies leading to the FDA's approval of imatinib (Gleevec®), a revolutionary, molecularly-targeted drug used to treat chronic myeloid leukemia; • Participated in the development of new therapies for Hodgkins’ and non-Hodgkin’s lymphoma; • Contributed to the understanding of how and why breast cancers spread, and to the development of new breast cancer treatments; • Identified the processes of blood cell formation, which led to a new treatment for blood diseases and solid tumor cancers through angiogenesis; • Discovered the molecular mechanism that causes some patients to be resistant to ibrutinib, an important drug used to treat mantle cell leukemia; and • Contributed to the use of interferon alfa and other biologics in treating myeloproliferative neoplasms (MPNs). In addition, CR&T continues to invest in education and community outreach. At our biennial MPN Patient Symposium, patients and family members learn about the latest developments from leading experts in the field. Through our support of an annual prostate cancer screening program in Jamaica, Queens, we enable underserved patients to access quality healthcare. We are deeply grateful to our donors and friends for their commitment to CR&T and the community we serve. For more information, please visit our website at www.crt.org or contact us at 212-288-6604 or brosenstein@crt.org.